Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS OLE long-term safety of cenerimod in systemic lupus erythematosus
2024-514354-67-00Phase 3Authorised
- Sponsor
- Viatris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-514354-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514354-67-00.